AstraZeneca

Open: 68.64 Close: 68.29 Change: -0.35

Are you looking for information about AstraZeneca Stock? We programmed an AI to summarize it for you.

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, quarter, consensus, cancer, drug, estimate, year, and the most common words in the summary are: astrazeneca, astrazenecas, news, drug, subscribe, see, top, . One of the sentences in the summary was: Chief Executive Pascal Soriot may leave company as soon as next year.. Other searches …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Astrazeneca revenue was $11.42 billion in the second quarter of 2023, up 6% from the prior quarter and beating analysts consensus estimates by $0.4 billion. Chief Executive Pascal Soriot may leave company as soon as next year.

Today's News

GlobalData tracks drug-specific phase transition and likelihood of approval scores. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK. EMA CHMP recommends approval for Modernas updated Covid-19 vaccine. Astrazeneca lung cancer drug works better with chemotherapy (1) AstraZenecas Tagrisso delayed worsening of advanced lung cancer longer. AstraZeneca PLC ADR is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The FDA granted Orphan Drug Designation for FASENRA for EGPA in 2018. Respiratory & Immunology, part of BioPharmaceuticals, is one of Astras main disease areas. Astrazeneca is expected to post earnings of $0.79 per share for the current quarter, representing a year-over-year change of -6%. The consensus earnings estimate for the next fiscal year of $4.15 indicates a change of +13.4% from a year ago. The size of the recent change in the consensus estimate, along with three other factors related to earnings. AstraZenecas Enhertu cancer drug Enherta was recommended by the European Medicines Agencys human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC) The drug is a specifically engineered HER2 directed antibody drug. AstraZeneca shares were down 3.3% at 1128 GMT, with two analysts citing to Reuters a report in the Mail on Sunday saying the drugmakers Chief Executive Pascal Soriot may leave the company as soon as next year. AstraZeneca revenue was $11.42 billion in the second quarter of 2023, up 6% from the prior quarter and beating analysts consensus estimates by $0.4 billion. AbbVies actual revenue beat consensus estimates in only four of the last ten quarters, five quarters less than AstraZecas. We believe Astra Zenecas is a more promising asset, which will be reflected in growth in higher return treasury throwingandan bench�� GENERAL RC Freddy AstraZeneca research and development expenditures have increased in recent years. In 2022, almost 23 percent of AstraZecas total revenue was expended on research. As of early 2022, Astrazeneca was projected to be among the worlds top six pharmaceutical companies. Analyst consensus calls AstraZeneca stock a Moderate Buy, supported by four Buy ratings and two Holds. With an average price target of $80.88, AstraZeca stock offers investors 21.44% upside.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

How much time have you spent trying to decide whether investing in AstraZeneca? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, quarter, consensus, cancer, drug, estimate, year, and the most common words in the summary are: astrazeneca, astrazenecas, news, drug, subscribe, see, top, . One of the sentences in the summary was: Chief Executive Pascal Soriot may leave company as soon as next year.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #astrazenecas #news #drug #subscribe #see #top.